IP Library Granted Patent US 9,700,721
Granted Patent B2
US 9,700,721 · App. 13/917,917 · Granted Jul 11, 2017

Stimulation method for treatment of ocular conditions

Inventors: Amy M. Goodman (San Francisco, CA); Anthony V. Caparso (San Francisco, CA)
Assignee: Autonomic Technologies, Inc.
A61N1/36046A61B17/24A61B17/3468A61N1/0526A61N1/3606A61B17/3211A61B2017/320052A61N1/0546A61N1/36053A61N1/36153A61N1/36157A61N1/36171A61N1/36175
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,700,721
App. No.
13/917,917
Granted
Jul 11, 2017
Kind
B2
Abstract

One aspect of the present disclosure relates to a method for modulating, suppressing or preventing an ocular disorder in a subject. One step of the method can include positioning at least one electrode on or proximate to at least one of a sphenopalatine ganglion (SPG), a sphenopalatine nerve (SN), a vidian nerve (VN), a greater petrosal nerve (GPN), a deep petrosal nerve (DPN), or a branch thereof, of the subject. Next, the at least one electrode can be activated to apply an electrical signal to at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.

Claims (21)

1. A method for modulating, suppressing or preventing an ocular disorder in a subject, the method comprising the steps of:

receiving at least one electrode on or proximate to at least one of a sphenopalatine ganglion (SPG), a sphenopalatine nerve (SN), a vidian nerve (VN), a greater petrosal nerve (GPN), a deep petrosal nerve (DPN), or a branch thereof, of the subject; and

activating the at least one electrode, wherein the at least one electrode is configured to apply an electrical signal to at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof to modulate, suppress or prevent the ocular disorder, the electrical signal having a frequency of about 1 to 1000 Hz, a pulse-width of about 0.04 to 2 ms, a current of about 0.05 to 100 mA, and a voltage of about 1 to 10 V; wherein the ocular disorder is mediated by autonomic or neurological dysfunction.

2. The method of claim 1 , wherein the electrical signal disrupts nerve signal generation in, or transmission through, at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.

3. The method of claim 1 , wherein the at least one electrode is received without penetrating the cranium, into the pterygopalatine fossa so that the at least one electrode is positioned on or proximate to at least one of the SPG, the SN, the VN, or the branch thereof.

4. The method of claim 1 , wherein the activating step generates heat insufficient to cause a lesion on at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.

5. The method of claim 1 , further including the step of adjusting the electrical signal without requiring an invasive procedure on the subject.

6. The method of claim 1 , wherein the at least one electrode is received proximate to the GPN, the DPN, or a branch thereof, via an intravascular route.

7. A method for modulating, suppressing or preventing a tearing disorder in a subject, the method comprising the steps of:

receiving at least one electrode on or proximate to at least one of a SPG, a SN, a VN, a GPN, a DPN, or a branch thereof, of the subject; and

activating the at least one electrode wherein the at least one electrode is configured to apply an electrical signal to at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof to modulate, suppress or prevent the tearing disorder, the electrical signal having a frequency of about 1 to 1000 Hz, a pulse-width of about 0.04 to 2 ms, a current of about 0.05 to 100 mA, and a voltage of about 1 to 10 V; wherein the tearing disorder is mediated by autonomic or neurological dysfunction.

8. The method of claim 7 , wherein the at least one electrode is received without penetrating the cranium, into the pterygopalatine fossa so that the at least one electrode is positioned on or proximate to at least one of the SPG, the SN, the VN, or the branch thereof.

9. The method of claim 7 , wherein the activating step generates heat insufficient to cause a lesion on at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.

10. The method of claim 7 , further including the step of adjusting the electrical signal without requiring an invasive procedure on the subject.

11. The method of claim 7 , wherein the at least one electrode is received proximate to the GPN, the DPN, or a branch thereof, via an intravascular route.

12. A method for modulating, suppressing or preventing a dry eye syndrome in a subject, the method comprising the steps of:

receiving at least one electrode on or proximate to at least one of a SPG, a SN, a VN, a GPN, a DPN, or a branch thereof, of the subject; and

activating the at least one electrode, wherein the at least one electrode is configured to apply an electrical signal to at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof to modulate, suppress, or prevent the dry eye syndrome, the electrical signal having a frequency of about 1 to 1000 Hz, a pulse-width of about 0.04 to 2 ms, a current of about 0.05 to 100 mA, and a voltage of about 1 to 10 V; wherein the dry eye syndrome is mediated by autonomic or neurological dysfunction.

13. The method of claim 12 , wherein the electrical signal disrupts nerve signal generation in, or transmission through, at least one of the SPG, the SN, the VN, the GPN, the DPN, or the branch thereof.

14. The method of claim 12 , wherein the at least one electrode is received without penetrating the cranium, into the pterygopalatine fossa so that the at least one electrode is positioned on or proximate to at least one of the SPG, the SN, the VN, or the branch thereof.

15. The method of claim 12 , wherein the at least one electrode is received proximate to the GPN, the DPN, or a branch thereof, via an intravascular route.

Assignments (6)
CHANGE OF NAME Recorded Jan 31, 2024
From: UNITY HA LLC
To: REALEVE, LLC
Reel/Frame 066403/0526 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2021
From: CRG SERVICING, LLC
To: AUTONOMIC TECHNOLOGIES, INC.
Reel/Frame 056753/0378 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2021
From: AUTONOMIC TECHNOLOGIES, INC.
To: AUTONOMIC (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Reel/Frame 056742/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2021
From: AUTONOMIC (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: UNITY HA LLC
Reel/Frame 056742/0596 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 30, 2015
From: AUTONOMIC TECHNOLOGIES, INC.
To: CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 037405/0600 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2013
From: GOODMAN, AMY; CAPARSO, ANTHONY V.
To: AUTONOMIC TECHNOLOGIES, INC.
Reel/Frame 030947/0449 →
Continuity (4)
Continuation In Part 13476224 · May 21, 2012
Continuation In Part 13470480 · May 14, 2012
Provisional Application 61659842 · Jun 14, 2012
Related Publication 20130304154A1 · Nov 14, 2013